Biosergen AB — Investor Relations & Filings

Biosergen AB is a clinical-stage biotechnology company developing innovative drugs to treat severe and resistant invasive fungal infections. The company's lead candidate, BSG005, is a genetically improved, broad-spectrum polyene macrolide. It is designed to be fungicidal, killing the fungus rather than only inhibiting its growth, and aims to provide a superior safety and potency profile compared to existing treatments. The primary target patient population is immunocompromised individuals, such as those with cancer, AIDS, or who have undergone organ transplants. BSG005 has completed a Phase 1 safety study and is advancing in clinical development. The candidate has received Orphan Drug Designation from the U.S. FDA and is protected by patents until 2043.